Business Material Contracts
Schedule 2.11(d)
Clinical Trials
Schedule 2.16
Financial Statements
Schedule 2.17
Insurance
Schedule 4.2(a)
Transition Teams
Schedule 4.5
List of Product lot numbers sold exclusively by Seller
Exhibits:
Exhibit A
Escrow Agreement
Exhibit B
Bill of Sale
Exhibit C
Patent License Assignment
Exhibit D
Trademark Assignment
Exhibit E-1
Seller FDA Letter (IND)
Exhibit E-2
Seller FDA Letter (NDA)
Exhibit F-1
Buyer FDA Letter (IND)
Exhibit F-2
Buyer FDA Letter (NDA)
Exhibit G
Assumption Agreement
Exhibit H
Seller Counsel Legal Opinion
Exhibit I
Buyer Counsel Legal Opinion
Exhibit J
Transition Plan
Exhibit K
Customer Notification
iii
TABLE OF DEFINED TERMS
Terms
Reference in Agreement
Accountant
4.18.(c)
Acquired Assets
1.1
Acquired Licenses
1.1(c)
Additional Assumption Documents
1.6.(b)(x)
Additional Transfer Documents
1.6.(b)(vii)
Affiliate
4.8.(b)
Agreed Amount
5.3.(b)
Agreement
Preamble
Allocation
1.8
AMP
4.12.(a)
Ancillary Documents
1.6.(b)(x)
ANDA
2.6
Assumed Contracts
1.1.(i)
Assumed Liabilities
1.3
Assumption Agreement
1.6.(b)(viii)
Bill of Sale
1.6.(b)(ii)
Books and Records
1.1.(j)
Business
Preamble
Business Day
1.6.(a)
Business Material Adverse Effect
2.1
Business Material Contracts
2.5.(a)
Buyer
Preamble
Buyer FDA Letter
1.6.(b)(vi)
Buyer Material Adverse Effect
3.1
Buyer Rights Chain Group
1.5(c)
CDAPCA
2.11(a)
Chargebacks
4.11.(b)
cGMP
2.7
Claim Amount
5.3.(b)
Claim Notice
5.3.(b)
Closing
1.6.(a)
Closing Date
1.6.(a)
Closing Date Purchase Price
1.5
CMS
4.12.(a)
Code
1.8.
Composition
Preamble
Confidential Information
4.1
Core Reps
5.5.(a)
CSA
2.11(a)
Damages
5.1, 5.3(a)
DEA
2.11(a)
Deductible
5.5.(a)
Escrow Agent
1.5(a)
iv
Terms
Reference in Agreement
Escrow Fund
1.5(a)
Escrow Agreement
1.5(a)
Excluded Assets
1.2
Excluded Liabilities
1.4
Excluded Tax Damages
5.5(a)
Exclusions
1.5(d)
FDA
1.6.(b)(v)
FDA Act
2.11(a)
Federal Ceiling Price
4.11(c)
First Additional Purchase Price Payment Date
1.5(a)(iv)
First Milestone Payment
1.5(a)(iv)
FSS
4.11(a)
GAAP
1.5(b)
Governmental Entity
2.2(c)
Health Authorities
2.11(a)
Health Laws
2.11(a)
HIPAA
2.11(h)
IND
2.11(b)
Indemnified Party
5.3(a)
Indemnifying Party
5.3(a)
Intellectual Property
2.4(a)
Investment Banker
2.15
Inventory Purchase Price
1.5(a)(ii)
Know-How
1.1(e)
Law
2.8
Laws
2.8
Lead Member
4.2(a)
Lead Members
4.2(a)
Liens
2.2(b)
Marketing Assets
1.1(g)
Medicaid Finished Product
4.12.(c)
Medical Information Phone Number
1.6(m)
NDA
2.11(b)
Net Sales
1.5(b)
Net Sales Report
4.19(a)
New Contact Number
4.23
Non-FAMP
4.11(a)
Order
2.4(e)
Other Assumed Liabilities
1.3(d)
Patent License Assignment
1.6(b)(iii)
Permits
1.1(d)
Permitted Liens
2.2(b)
PHS
4.11(d)
PO Purchase Price
1.5(a)(iii)
Product
Preamble
v
Terms
Reference in Agreement
Product Inventory
1.1(f)
Purchase Price
1.5(a)(v)
Rebates
4.12(b)
Report Deadline
4.19(a)
Returns Agreed Amount
5.3(c)
Returns Claim Amount
5.3(c)
Returns Claim Notice
5.3(c)
Returns Escrow Fund
1.5(a)
Second Additional Purchase Price Payment Date
1.5(a)(v)
Second Milestone Payment
1.5(a)(v)
Seller
Preamble
Seller Accounts Receivable
1.2(b)
Seller Brands
1.2(d)
Seller Disclosure Schedule
ARTICLE II
Seller FDA Letter
1.6(b)(v)
Seller Licensed Patents
1.1(c)
Seller Permits
2.9
Seller Product Returns
4.5(a)
Seller's Knowledge
6.12
Tax Payee
4.15(c)
Tax Payor
4.15(c)
Tax Returns
2.3(a)
Taxes
2.3(a)
Taxing Authority
2.3(a)
Territory
1.1(c)
Third Party Claim Amount
5.3(a)
Third Party Claim Notice
5.3(a)
Trademark Assignment
1.6 (b)(iv)
Trademark Period
4.7(b)
Transaction Fees
4.17
Transition Plan
4.2(a)
Transition Team
4.2(a)
Transition Teams
4.2(a)
Transfer Taxes
1.7
Transferred Domain Names
1.1(b)